Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam

K. J. Meador, A. Gevins, D. W. Loring, L. K. McEvoy, P. G. Ray, M. E. Smith, G. K. Motamedi, B. M. Evans, C. Baum

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

BACKGROUND: The relative effects of levetiracetam (LEV) and carbamazepine (CBZ) on cognitive and neurophysiologic measures are uncertain. METHODS: The effects of LEV and CBZ were compared in healthy adults using a randomized, double-blind, two-period crossover design. Outcome measures included 11 standard neuropsychological tests and the score from a cognitive-neurophysiologic test of attention and memory. Evaluations were conducted at screening, baseline pre-drug treatment, end of each maintenance phase (4 weeks), and end of each washout period after drug treatment. RESULTS: A total of 28 adults (17 women) with mean age of 33 years (range 18 to 51) completed the study. Mean maintenance doses (±SD) were CBZ = 564 mg/day (110) and LEV = 2,000 mg/day (0). CBZ was adjusted to mid-range therapeutic level. Mean serum levels (±SD) were CBZ = 7.5 mcg/mL (1.5) and LEV = 32.2 mcg/mL (11.2). An overall composite score including all measures revealed worse effects for CBZ compared to LEV (p ≤ 0.001) in the primary analysis and for CBZ (p ≤ 0.001) and LEV (p ≤ 0.05) compared to non-drug in secondary analyses. Across the 34 individual variables, CBZ was worse than LEV on 44% (15/34); none favored CBZ. Compared to the non-drug average, CBZ was worse for 76% (26/34), and LEV was worse for 12% (4 of 34). Sensitivity and specificity of standard neuropsychological tests and the cognitive-neurophysiologic test were determined to direct future studies; detection was most accurate by the cognitive-neurophysiologic test. CONCLUSIONS: Levetiracetam produces fewer untoward neuropsychological and neurophysiologic effects than carbamazepine in monotherapy at the dosages and timeframes employed in this study.

Original languageEnglish (US)
Pages (from-to)2076-2084
Number of pages9
JournalNeurology
Volume69
Issue number22
DOIs
StatePublished - Jan 1 2007

Fingerprint

etiracetam
Carbamazepine
Neuropsychological Tests

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Meador, K. J., Gevins, A., Loring, D. W., McEvoy, L. K., Ray, P. G., Smith, M. E., ... Baum, C. (2007). Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam. Neurology, 69(22), 2076-2084. https://doi.org/10.1212/01.wnl.0000281104.55418.60

Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam. / Meador, K. J.; Gevins, A.; Loring, D. W.; McEvoy, L. K.; Ray, P. G.; Smith, M. E.; Motamedi, G. K.; Evans, B. M.; Baum, C.

In: Neurology, Vol. 69, No. 22, 01.01.2007, p. 2076-2084.

Research output: Contribution to journalArticle

Meador, KJ, Gevins, A, Loring, DW, McEvoy, LK, Ray, PG, Smith, ME, Motamedi, GK, Evans, BM & Baum, C 2007, 'Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam', Neurology, vol. 69, no. 22, pp. 2076-2084. https://doi.org/10.1212/01.wnl.0000281104.55418.60
Meador KJ, Gevins A, Loring DW, McEvoy LK, Ray PG, Smith ME et al. Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam. Neurology. 2007 Jan 1;69(22):2076-2084. https://doi.org/10.1212/01.wnl.0000281104.55418.60
Meador, K. J. ; Gevins, A. ; Loring, D. W. ; McEvoy, L. K. ; Ray, P. G. ; Smith, M. E. ; Motamedi, G. K. ; Evans, B. M. ; Baum, C. / Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam. In: Neurology. 2007 ; Vol. 69, No. 22. pp. 2076-2084.
@article{0e9679af536f4836aa999b30ba155592,
title = "Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam",
abstract = "BACKGROUND: The relative effects of levetiracetam (LEV) and carbamazepine (CBZ) on cognitive and neurophysiologic measures are uncertain. METHODS: The effects of LEV and CBZ were compared in healthy adults using a randomized, double-blind, two-period crossover design. Outcome measures included 11 standard neuropsychological tests and the score from a cognitive-neurophysiologic test of attention and memory. Evaluations were conducted at screening, baseline pre-drug treatment, end of each maintenance phase (4 weeks), and end of each washout period after drug treatment. RESULTS: A total of 28 adults (17 women) with mean age of 33 years (range 18 to 51) completed the study. Mean maintenance doses (±SD) were CBZ = 564 mg/day (110) and LEV = 2,000 mg/day (0). CBZ was adjusted to mid-range therapeutic level. Mean serum levels (±SD) were CBZ = 7.5 mcg/mL (1.5) and LEV = 32.2 mcg/mL (11.2). An overall composite score including all measures revealed worse effects for CBZ compared to LEV (p ≤ 0.001) in the primary analysis and for CBZ (p ≤ 0.001) and LEV (p ≤ 0.05) compared to non-drug in secondary analyses. Across the 34 individual variables, CBZ was worse than LEV on 44{\%} (15/34); none favored CBZ. Compared to the non-drug average, CBZ was worse for 76{\%} (26/34), and LEV was worse for 12{\%} (4 of 34). Sensitivity and specificity of standard neuropsychological tests and the cognitive-neurophysiologic test were determined to direct future studies; detection was most accurate by the cognitive-neurophysiologic test. CONCLUSIONS: Levetiracetam produces fewer untoward neuropsychological and neurophysiologic effects than carbamazepine in monotherapy at the dosages and timeframes employed in this study.",
author = "Meador, {K. J.} and A. Gevins and Loring, {D. W.} and McEvoy, {L. K.} and Ray, {P. G.} and Smith, {M. E.} and Motamedi, {G. K.} and Evans, {B. M.} and C. Baum",
year = "2007",
month = "1",
day = "1",
doi = "10.1212/01.wnl.0000281104.55418.60",
language = "English (US)",
volume = "69",
pages = "2076--2084",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "22",

}

TY - JOUR

T1 - Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam

AU - Meador, K. J.

AU - Gevins, A.

AU - Loring, D. W.

AU - McEvoy, L. K.

AU - Ray, P. G.

AU - Smith, M. E.

AU - Motamedi, G. K.

AU - Evans, B. M.

AU - Baum, C.

PY - 2007/1/1

Y1 - 2007/1/1

N2 - BACKGROUND: The relative effects of levetiracetam (LEV) and carbamazepine (CBZ) on cognitive and neurophysiologic measures are uncertain. METHODS: The effects of LEV and CBZ were compared in healthy adults using a randomized, double-blind, two-period crossover design. Outcome measures included 11 standard neuropsychological tests and the score from a cognitive-neurophysiologic test of attention and memory. Evaluations were conducted at screening, baseline pre-drug treatment, end of each maintenance phase (4 weeks), and end of each washout period after drug treatment. RESULTS: A total of 28 adults (17 women) with mean age of 33 years (range 18 to 51) completed the study. Mean maintenance doses (±SD) were CBZ = 564 mg/day (110) and LEV = 2,000 mg/day (0). CBZ was adjusted to mid-range therapeutic level. Mean serum levels (±SD) were CBZ = 7.5 mcg/mL (1.5) and LEV = 32.2 mcg/mL (11.2). An overall composite score including all measures revealed worse effects for CBZ compared to LEV (p ≤ 0.001) in the primary analysis and for CBZ (p ≤ 0.001) and LEV (p ≤ 0.05) compared to non-drug in secondary analyses. Across the 34 individual variables, CBZ was worse than LEV on 44% (15/34); none favored CBZ. Compared to the non-drug average, CBZ was worse for 76% (26/34), and LEV was worse for 12% (4 of 34). Sensitivity and specificity of standard neuropsychological tests and the cognitive-neurophysiologic test were determined to direct future studies; detection was most accurate by the cognitive-neurophysiologic test. CONCLUSIONS: Levetiracetam produces fewer untoward neuropsychological and neurophysiologic effects than carbamazepine in monotherapy at the dosages and timeframes employed in this study.

AB - BACKGROUND: The relative effects of levetiracetam (LEV) and carbamazepine (CBZ) on cognitive and neurophysiologic measures are uncertain. METHODS: The effects of LEV and CBZ were compared in healthy adults using a randomized, double-blind, two-period crossover design. Outcome measures included 11 standard neuropsychological tests and the score from a cognitive-neurophysiologic test of attention and memory. Evaluations were conducted at screening, baseline pre-drug treatment, end of each maintenance phase (4 weeks), and end of each washout period after drug treatment. RESULTS: A total of 28 adults (17 women) with mean age of 33 years (range 18 to 51) completed the study. Mean maintenance doses (±SD) were CBZ = 564 mg/day (110) and LEV = 2,000 mg/day (0). CBZ was adjusted to mid-range therapeutic level. Mean serum levels (±SD) were CBZ = 7.5 mcg/mL (1.5) and LEV = 32.2 mcg/mL (11.2). An overall composite score including all measures revealed worse effects for CBZ compared to LEV (p ≤ 0.001) in the primary analysis and for CBZ (p ≤ 0.001) and LEV (p ≤ 0.05) compared to non-drug in secondary analyses. Across the 34 individual variables, CBZ was worse than LEV on 44% (15/34); none favored CBZ. Compared to the non-drug average, CBZ was worse for 76% (26/34), and LEV was worse for 12% (4 of 34). Sensitivity and specificity of standard neuropsychological tests and the cognitive-neurophysiologic test were determined to direct future studies; detection was most accurate by the cognitive-neurophysiologic test. CONCLUSIONS: Levetiracetam produces fewer untoward neuropsychological and neurophysiologic effects than carbamazepine in monotherapy at the dosages and timeframes employed in this study.

UR - http://www.scopus.com/inward/record.url?scp=36448972778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36448972778&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000281104.55418.60

DO - 10.1212/01.wnl.0000281104.55418.60

M3 - Article

VL - 69

SP - 2076

EP - 2084

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 22

ER -